Axol Bioscience News Today

Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The

The 2023 Sir David Cooksey Prize in Translation has been awarded to postdoctoral researcher Anaid Benitez for her work on tumour diagnostics and her leadership of the Crick Science Entrepreneur Network (CSEN). Click to read more...

DUBLIN--(BUSINESS WIRE)--The "Global Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Forecast to 2028" report has been added to Resea...

/PRNewswire/ -- The "Global Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal),...

Dublin, Sept. 08, 2023 (GLOBE NEWSWIRE) -- The

/PRNewswire/ -- The primary cells industry is poised for significant advancements and growth in the near future. As researchers and pharmaceutical companies...

Axol Bioscience Ltd, a pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.

Axol Bioscience Ltd, a pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.

Together, an extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification. Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell

Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.